Manufacturing Daily Summary
Manufacturing Daily Summary: What Happened on October 27, 2026
Regeneron extends Inmazeb supply contract through 2031 for nearly $270 million
Thermo Fisher plans KinetiSol equipment installations in Oregon and Ohio.
-
B
Today in brief
Regeneron extended its contract to supply the U.S. government with Inmazeb through 2031, in an agreement worth nearly $270 million.1 Thermo Fisher plans to install KinetiSol equipment in Bend, Oregon, and Cincinnati, Ohio, making it the only third-party contract development and manufacturing organization offering the Formulator.2
Also worth knowing
-
The extended Inmazeb contract builds on Regeneron’s collaboration with the Biomedical Advanced Research and Development Authority, which began in 2020. The additional doses will support national emergency stockpiles.1
-
B
Thermo Fisher added KinetiSol, a solvent-free technology for making poorly soluble drugs easier to absorb, to its offerings in 2026. It has installed a lab-scale system in Bend and plans to install a late-stage unit in Cincinnati by the second quarter of 2027.2
Also published
- Platform Formulations Shift Risk Downstream, Pfizer’s Dr Stephanie Johnson Says BioPharm International
- Why Lane Security Comes Before Sustainability in Packaging Selection Pharmaceutical Commerce
- Modernize Patient Support Services: Your 3-Step Guide Pharmaceutical Executive
- Why BMS Is Screening CMO Partners for Digital Capabilities Pharmaceutical Commerce
- Reliability in life sciences logistics: What good looks like pharmaphorum
- The stranded asset problem in microbial custom manufacturing Labiotech